Please assess the completion status of the following clinical trial:

Trial Title: Trial of Colchicine Versus Prednisone for the Treatment of Acute CPPD Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient aged 65 and older~* Patient with mono/polyarticular CPPD acute arthritis~* Hospitalized patient (without infectious syndrome considered insufficiently controlled by the clinicians and diabetic decompensation)~* Diagnosis confirmed :~* By the evidence of CPP crystals on synovial fluid examination.~* By the existence of a typical clinical arthritis (joint pain, erythema, swelling, maximal intensity in less than 24h) AND presence of chondrocalcinosis signs in knee, wrists, or pubic symphysis on plain X-rays or crowned tooth in cervical rachis scan.~* Pain VAS ≥ 40/100 at the enrollment~* Duration of symptoms evolution for less than 36h.~* No prior intake of oral steroids, colchicine or NSAIDs for this acute arthritis.~* Signed patient's consent.~* Affiliation to a social security scheme.~Exclusion Criteria:~* Contraindication to colchicine (creatinine clearance below 30ml/min, severe hepatic dysfunction, macrolide or ongoing pristinamycin or macrolid treatment, ...) or corticoids utilization (uncontrolled diabetes, uncontrolled progressive infection, uncontrolled arterial hypertension...)~* Severe cognitive disorders that does not allow patient to evaluate his pain.~* Patient under guardianship, curatorship~* Patient receiving morphinic analgesia.~* Gout history or presence of monosodium urate crystals at the examination of the synovial fluid.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Colchicine (Type: ACTIVE_COMPARATOR): Patients assigned to this group will receive the Colchicine opocalcium 1mg treatment.
- Prednisone (corticoids) (Type: EXPERIMENTAL): Patients assigned to this group will receive Prednisone : Cortancyl 20mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).